May 30th 2024
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss how to factor in trastuzumab deruxtecan in advanced biliary tract cancer.
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.
May 29th 2024
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the clinical implications of 3-year survival data from TOPAZ-1 in advanced biliary tract cancer.
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient put the TOPAZ-1 data into context for patients with advanced biliary tract cancer.
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.
Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, discuss a case of advanced biliary tract cancer with a patient.
Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, and a patient discuss prognosis and standard-of-care treatment for patients with advanced biliary tract cancer.
August 9th 2023
The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.
Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.
August 3rd 2023
Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.
Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.
July 28th 2023
Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.
Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.
July 19th 2023
Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.
The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.
July 12th 2023
Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.
Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.
March 22nd 2023
Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.
Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.